The Montreal Heart Institute has announced that its Research Center is today launching a COVID-19 clinical study in Canada to determine whether short-term treatment would reduce the risk of pulmonary complications and related deaths.   

The clinical study, named COLCORONA, coordinated by the Montreal Health Innovations Coordinating Center (MHICC), is funded by the Quebec government and supported by Pharmascience plus IT and management consulting firm CGI.

COLCORONA will evaluate the phenomenon of major inflammatory storm present in adults suffering from severe complications related to COVID-19. The researchers hypothesized that the treatment could reduce the complications associated with COVID-19. The clinical study will involve the recruitment of approximately 6000 participants followed for 30 days. Initial results will be available a few days after study completion.

Participants eligibility criteria:

  • Be tested positive for COVID-19;
  • Be 40 years and over;
  • Not hospitalized;
  • Be willing to take the drug or placebo daily for 30 days;
  • Be willing to participate in two follow-up calls by phone or videoconference;

Women who do not take contraceptives, those who are pregnant and those who are breastfeeding are not eligible for the clinical study.

People with a positive COVID-19 diagnosis who are interested in participating in the clinical study are encouraged to speak to their health care professional or call 1-877-536-6837.  Phone lines will be open as of 7h00 AM EDT Monday March 23rd.

To learn more about the COLCORONA clinical study, go to www.colcorona.org

Read more about: CGI